ArticleDigestive diseases and sciences2026
The Carcinogenic Role of HMGB1 and NF-κB in Gastric Adenocarcinoma.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the expression levels of high mobility group box 1 (HMGB1) and nuclear factor kappa-B (NF-κB) and to characterize their relationship in gastric adenocarcinoma.
methodsThe expression data for HMGB1 and NF-κB from the GEO database were analyzed to assess expression levels and prognostic relevance in gastric cancer. Immunohistochemistry was performed to verify their expressions in primary gastric adenocarcinoma tissues and adjacent non-tumor tissues. Next, we collected clinicopathologic data of patients with gastric cancer and analyzed the correlations between HMGB1 and NF-κB expression. Furthermore, we assessed the impact of HMGB1 and NF-κB expression on the survival time of gastric cancer patients using Kaplan-Meier survival analysis. All statistical analyses were conducted using GraphPad Prism 9.
resultThe results showed that HMGB1 and NF-κB were significantly higher than normal tissues, which were significantly correlated with survival prognosis. IHC analysis further confirmed high positivity rates for HMGB1 (81.76%) and NF-κB (75%) in gastric adenocarcinoma, respectively. Furthermore, higher expression levels of HMGB1 and NF-κB were associated with shorter survival time of gastric cancer patients. The expression level of HMGB1 or NF-κB was correlated with tumor size, depth of invasion, and clinical stage. Finally, we demonstrated that there is a correlation between the expression of HMGB1 and NF-κB.
conclusionPrevious studies focused on mechanistic regulation, while systematic clinicopathologic co-expression analysis of HMGB1 and NF-κB in human gastric adenocarcinoma tissues remains limited. This work provides novel evidence that the co-expression of HMGB1 and NF-κB is associated with key clinicopathologic factors and survival outcomes in gastric adenocarcinoma.
Indexed as
Identifiers
41917528What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.